How Russian investments reacted to COVID

Europe’s sustainability tech sector continues its aggressive march toward circular economy solutions, with hygiene products representing one of the most challenging waste streams to tackle. Planet Smart has secured €920K in pre-seed funding led by General Inception and Vertical Venture Partners to address the mounting plastic waste crisis in disposable nappies and sanitary pads. The London-based startup’s approach comes at a critical moment for European environmental policy, as the EU prepares stricter regulations on single-use plastics and member states face mounting pressure to meet ambitious waste reduction targets by 2030. Sustainable hygiene funding attracts specialist investors General Inception and Vertical Venture Partners led the round, reflecting growing investor appetite for deep-tech sustainability solutions addressing massive market inefficiencies. Both firms have built portfolios around circular economy innovations, particularly those tackling traditionally difficult waste streams. “The hygiene products market generates over 45 billion units of waste annually in Europe alone, with conventional recycling unable to handle the complex material composition,” noted a partner at General Inception. “Planet Smart’s technology offers the first commercially viable pathway to process these materials at scale.” The investor backing signals institutional recognition that sustainable alternatives to petroleum-based hygiene products represent significant market opportunity rather than mere environmental virtue signalling. European venture capital increasingly prioritises startups with clear regulatory tailwinds and defensible technology moats. European market advantages drive expansion strategy Planet Smart’s technology platform addresses material composition challenges that have stymied recycling efforts for decades. Traditional hygiene products combine multiple polymer layers with absorbent materials, creating separation difficulties that render most items unrecyclable. The company plans to deploy funding across product development and pilot partnerships with European manufacturers, capitalising on increasingly stringent Extended Producer Responsibility regulations across EU member states. Unlike US counterparts focused purely on bio-based alternatives, Planet Smart’s approach works with existing supply chains. “European manufacturers face mounting compliance costs and supply chain disruption from environmental regulations,” explained Planet Smart’s CEO. “Our solution integrates with current production processes whilst dramatically reducing end-of-life environmental impact.” The startup targets partnerships with major European hygiene brands seeking to differentiate through genuine sustainability credentials rather than superficial packaging changes. Initial pilots are planned across three EU markets by Q3 2025. This funding positions Planet Smart within Europe’s broader cleantech renaissance, where regulatory certainty creates competitive advantages over markets with less predictable environmental policy. The company’s timing capitalises on both investor enthusiasm and policy momentum converging around circular economy solutions.

The European biotech sector is experiencing renewed investor confidence, particularly in diagnostic technologies that promise to revolutionise early disease detection. This trend reflects growing demand for precision healthcare solutions across fragmented European markets, where regulatory frameworks increasingly favour innovative diagnostic platforms. InvenireX, a UK-based biotech startup, has secured €2.4M (£2M) in seed funding to advance its proprietary disease detection platform. The round positions the company to accelerate commercialisation efforts across European markets, where demand for rapid diagnostic solutions has intensified following recent healthcare challenges. The funding represents a significant milestone for European diagnostic innovation, particularly as investors seek technologies that can navigate complex regulatory environments whilst delivering scalable solutions across diverse healthcare systems. DSW Ventures leads biotech diagnostics funding round DSW Ventures spearheaded the investment, recognising InvenireX’s potential to address critical gaps in European diagnostic capabilities. The venture firm’s thesis centres on supporting technologies that can achieve regulatory approval whilst maintaining commercial viability across multiple European jurisdictions. “InvenireX represents exactly the kind of deep-tech innovation we seek in the European biotech landscape,” noted a DSW Ventures representative. “Their platform addresses genuine market needs whilst leveraging regulatory advantages available to UK-based diagnostics companies.” The investor’s involvement extends beyond capital provision, offering strategic guidance on navigating European regulatory frameworks and accessing key healthcare networks across major markets. This support proves particularly valuable given the complexity of achieving CE marking and national approvals across different European territories. DSW Ventures’ portfolio strategy focuses on companies positioned to benefit from European regulatory harmonisation whilst maintaining competitive advantages through proprietary technologies. Disease detection platform targets European market expansion InvenireX’s diagnostic technology offers rapid disease detection capabilities designed specifically for European healthcare environments. The platform addresses growing demand for point-of-care solutions that can operate effectively within diverse regulatory frameworks whilst delivering consistent performance metrics. The funding will accelerate product development and support market entry strategies across key European territories. InvenireX plans to leverage its UK base to access both European markets and maintain regulatory flexibility as Brexit-related healthcare agreements stabilise. “We’re building diagnostic capabilities that reflect European healthcare realities,” explained the InvenireX leadership team. “Our platform recognises that successful deployment requires understanding local regulatory requirements whilst maintaining technical excellence.” The company’s go-to-market strategy emphasises partnerships with European healthcare providers, recognising that adoption requires demonstrable clinical outcomes alongside cost-effectiveness metrics. This approach aligns with European healthcare systems’ emphasis on evidence-based procurement decisions. The European diagnostic market presents significant opportunities, particularly as healthcare systems prioritise technologies that can reduce costs whilst improving patient outcomes. InvenireX’s platform addresses these dual requirements through innovative detection methodologies. This funding round signals growing investor confidence in European biotech innovations, particularly technologies that can achieve regulatory compliance whilst addressing genuine market needs. For the broader European startup ecosystem, it demonstrates that deep-tech solutions continue attracting meaningful investment despite economic uncertainties.

European brands are increasingly struggling to maintain visibility across fragmented digital channels, creating a €2.3 billion addressable market for AI-powered brand monitoring solutions. This challenge has become particularly acute as privacy regulations like GDPR reshape how consumer data flows across the continent’s diverse market landscape. Berlin-based Peec AI has secured €18 million in Series A funding to address this growing demand. The round was led by Singular, with participation from existing investors who recognise the strategic importance of brand intelligence in an increasingly complex European digital ecosystem. Series A funding strengthens European AI infrastructure Singular’s investment thesis centres on Peec AI’s ability to process multilingual brand data across Europe’s 27 markets simultaneously. Unlike US-focused competitors, Peec AI’s platform natively handles European languages and regulatory requirements, giving brands granular visibility into local market performance without compromising data sovereignty. “We’re seeing unprecedented demand from European brands that need to understand their visibility across markets with different languages, currencies, and consumer behaviours,” said a spokesperson from Singular. “Peec AI’s approach recognises that European brand management requires fundamentally different infrastructure than what works in the homogeneous US market.” The funding positions Peec AI to compete directly with Silicon Valley incumbents who have struggled to adapt their products for European regulatory compliance and multilingual requirements. AI-powered brand intelligence captures European market complexity Peec AI’s platform uses machine learning to track brand mentions, sentiment, and competitive positioning across digital channels in real-time. The company has developed proprietary algorithms that account for cultural nuances in brand perception across different European markets. The funding will accelerate product development focused on GDPR-compliant data collection and expand the engineering team across Berlin and other European tech hubs. Peec AI plans to triple its workforce over the next 18 months, with particular emphasis on recruiting multilingual AI engineers who understand European market dynamics. “European brands face challenges that simply don’t exist in other markets,” explained Peec AI’s leadership team. “Our AI needs to understand that a brand campaign succeeding in Germany might fail in France for cultural reasons that traditional analytics miss completely.” This funding round reflects growing investor confidence in European AI startups that solve specifically European problems. As privacy regulations tighten globally, Peec AI’s privacy-first architecture positions the company to expand beyond Europe while maintaining its competitive advantage in complex regulatory environments.